| Trial ID: | L0121 |
| Source ID: | NCT03574363
|
| Associated Drug: |
Kbp-5074 0.25 Mg Tablet
|
| Title: |
Phase 2b Study of KBP-5074 in Subjects With Uncontrolled Hypertension and Advanced Chronic Kidney Disease
|
| Acronym: |
BLOCKCKD
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT03574363/results
|
| Conditions: |
Chronic Kidney Diseases|Hypertension
|
| Interventions: |
DRUG: KBP-5074 0.25 mg tablet|DRUG: KBP-5074 0.5 mg tablet
|
| Outcome Measures: |
Primary: Systolic Blood Pressure, Change in trough cuff resting seated SBP from baseline to Day 84., Baseline to Day 84 | Secondary: Diastolic Blood Pressure, Change in trough cuff seated DBP from baseline to Day 84, Baseline to Day 84|UACR, Change in UACR from baseline to Day 84, Baseline to Day 84 | Other: Total KBP-5074 Concentration, Total KBP-5074 concentration, Day 84
|
| Sponsor/Collaborators: |
Sponsor: KBP Biosciences | Collaborators: Worldwide Clinical Trials
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
162
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2018-04-25
|
| Completion Date: |
2020-08-05
|
| Results First Posted: |
2024-03-21
|
| Last Update Posted: |
2024-03-21
|
| Locations: |
KBP Biosciences USA Inc, Princeton, New Jersey, 08540, United States|Worldwide Clinical Trials, Morrisville, North Carolina, 27560, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT03574363
|
